OPKO Health, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31)
OPKO Health, Inc. (OPK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) of $3.40 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-18.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue · last filed 2013-03-18
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2012 was $3.40M, a 46.88% decline from fiscal 2011.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2011 was $6.40M, a 88.24% increase from fiscal 2010.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2010 was $3.40M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 12 month |
|---|---|
| 2012-12-31 | $3.40M 10-K · filed 2013-03-18 |
| 2011-12-31 | $6.40M 10-K · filed 2013-03-18 |
| 2010-12-31 | $3.40M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |